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Oscar Wilde, ‘‘The Importance of Being Earnest’’
And so it is with the immune system. Memory T
cells are a critical component of the adaptive immune
system. Our ability to respond rapidly to antigens/
pathogens that we have been exposed to previously is
at the heart of the adaptive immune system. In general,
these memory T cells allow protection of the host to
pathogens that the individual has previously encoun-
tered and/or been vaccinated against. The secondary
response is rapid and more potent, leading to a rapid
clearance of the offending agent. Not surprisingly,
this population has also been explored in their contri-
bution to graft-versus-host disease (GVHD).
T CELLS IN HEMATOPOIETIC CELL TRANSPLANTATION
T cells have been clearly implicated in the patho-
genesis of acute GVHD (aGVHD). There are exten-
sive clinical data demonstrating that rigorous T cell
depletion (TCD) abrogates aGVHD. Unfortunately,
in many clinical settings, this process can result in
loss of facilitation of engraftment as well as high inci-
dence of relapses because of the loss of the graft-
versus-tumor effect.
The ability of the host to recover normal adaptive
immunity is a centerpiece for successful allogeneic
hematopoietic stem cell transplantation (HSCT). The
recovery of normal T cells is a portion, albeit an im-
portant one, of normal immunity. The other cells are
also important such as dendritic cells, B cells, mono-
cytes, macrophages, and the recovery of the innate
immune system. Recovery of normal numbers of T
cells and normal function is governed by many factors
such as the type of preparatory regimen, the status of
the thymus and secondary lymphoid organs, homeo-
static proliferation of donor and residual recipient
T cells, regulation of T cell apoptosis, presence of
harmful immunesuppressants such as calcineurin in-
hibitors or steroids, or possible beneficial immunesup-
pressants such as sirolimus.T CELL DEVELOPMENT
The ontogeny of T cells and its T has been exten-
sively studied [1-4]. T cells are generated from hemato-
poietic stem cells (HSC) found in the bone marrow.
Common lymphoid progenitors give rise to T cell
precursors or immature thymocytes. These cells
populate the thymus initially as double negative cells
(CD42CD82). As these cells mature, they become
double positive (CD41CD81) before becoming ma-
ture T cells that are single positive (CD41 or CD81).
These single positive cells then egress from the thymus
into the peripheral circulation.
The majority of the immature thymocytes actually
never leave the thymus. There is an intricate tightly
regulated 2-step selection process that determines
which T cells will be found in the circulation [5].
The first step is termed positive selection. Here in
the cortex of the thymus, the double positive T cells
that can bind self-antigens in the context of the appro-
priate major histocompatibility complex (MHC) of the
host’s thymic epithelial cells are given a survival signal.
Those cells that bind MHC class II molecules become
single positive CD41 cells, whereas those that bind
MHC class I will become single positive CD81 cells.
All the other T cells that are not able to bind self-
antigens undergo apoptotic cell death.
This first step is fraught with the danger of engen-
dering autoimmune T cells because each of the posi-
tively selected T cell can recognize self-antigens.
Thus, a second equally negative selection step needs
to occur. In this process, the positively selected thymo-
cytes move to the medulla where they are presented
with self-antigens in the context of the appropriate
MHC by professional antigen-presenting cells
(APCs) such as dendritic cells or macrophages. Those
cells that bind with too high affinity to self-antigens are
given a signal to undergo apoptosis. This process
ensures that the majority of the highly autoreactive T
cells do not slip into the peripheral blood where they
may wreck havoc by causing an autoimmune process.17
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regulatory T cells as well.
NAI¨VE VERSUS MEMORY T CELLS
T cells that have undergone positive and negative
selection egress from the thymus into the circulation.
These cells will circulate sampling antigens presented
in the context of their respective MHC molecules.
Naı¨ve cells are fully mature T cells, but have not yet
encountered the appropriate antigen that its T cell
receptor can recognize. Naı¨ve T cells express L-
selectin (CD62L) and lack or have low expression of
CD44 and activation markers such as CD25 and
CD69. They also do not have any of the edited iso-
forms of CD45 (they are CD45RA versus memory T
cells are CD45RO or RB). Naı¨ve cells are thought to
be relatively quiescent and do not divide until they
encounter their antigen. They require IL-7 and
IL-15 for homeostatic survival.
Naı¨ve T cells remain in this quiescent stage until
they encounter the specific antigen to which its
T cell receptor is targeted. The recognition of its cog-
nate antigen triggers the naı¨ve T cell to respond. If sec-
ondary signals in the form of costimulatory molecules
occurs, that cell initiates the adaptive immune
response. The naı¨ve T cells produce IL-2, proliferate,
and acquire an activated phenotype (CD251, CD441,
CD691) with a drop in the expression of L-selectin
(CD62Llow). This response may occur in a CD41
cell leading to a helper T cell response or in a CD81
cell leading to a cytotoxic response.
Encounter with the specific antigen drives a signif-
icant proliferation of the specific T cell clones to
respond against the antigen. For example, if a patient
develops influenza for the first time, then the specific
naı¨ve T cells for the immunodominant influenza pep-
tides will proliferate. The CD41 helper T cells pro-
duce cytokines and the cytotoxic CD81 cells will
destroy cells infected with the influenza virus and rid
the host of the infection. In this process, many of these
antigen specific cells will undergo apoptosis. As the in-
fection dies down (ie, there is a drop off in the amount
of influenza specific antigen), some of the antigen spe-
cific cells will become memory T cells, whereas others
will become regulatory T cells, thus decreasing the
nflammatory immune response.
Memory T cells are those lymphocytes that have
encountered antigen and mounted a response against
such an antigen and thus are no longer antigen naı¨ve
[6]. These cells are also normally in a quiescent state.
If they encounter the same specific antigen, for exam-
ple the same influenza virus, they will produce a rapid
and robust immune response characterized by prompt
proliferation, production of inflammatory cytokines
and rapid clearance of the virus.There are at least 3 populations of CD81 memory
T cells and probably similar CD41 cells. Broadly
speaking, they are central versus effector memory T
cells [7]. Central memory T cells are thought of as
memory ‘‘stem cells.’’ These cells tend to be long lived
and carry the essential imprint of previous antigen
exposure. These cells are thought to give rise to long-
lived immunologic memory. The cells express L-selec-
tin (CD62L1) and the chemokine receptor CCR7.
They secrete IL-2 but not IL-4 or interferon-gamma.
Effector memory T cells tend to express molecules
with cytotoxic function. These effector memory cells
(TEM or TEMRA) tend to produce cytokines such as in-
terferon-gamma and IL-4. The TEM cells do not ex-
press CD62L or CCR7. Although CD45RA isoforms
have been used to differentiate naı¨ve (CD45RA) from
memory T cells (CD45RO), some of the memory T
cells will revert back to CD45RA and thus this marker
alone is not absolute.
MEMORY T CELLS AND PREVENTION OF GVHD
As mentioned above, T cell depletion (TCD),
whereas effective, can be associated with higher inci-
dence of infection, lack of engraftment and relapse.
There have been many attempts to parse the T cell sub-
sets in different manners to overcome some of the
concerns regarding these 3 complications. Examples
of these include use of CD4, CD8, CD6, CD25, and
CD69 positive or negative selection process for the ini-
tial graft as well as use of such markers for donor lym-
phocyte infusions. Some of these approaches remain
promising in early trials. One other method could be
to parse T cells into a memory versus a naı¨ve phenotype
to ascertain whether there is a difference in the inci-
dence of GVHD based on these 2 broad T cell popula-
tions. What follows later from the summaries of Drs.
Shlomchik and Chen are our current understanding
of the contributions of the population of naı¨ve versus
memory T cells in aGVHD models and in human
mixed lymphocyte cultures. It is hoped that such ap-
proaches will allow the beginnings of engineering
a graft that contains most of the positive cellular com-
ponents without the allospecific GVHD inducing cells.
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Immunobiology, Yale University School of Medicine, New Haven, ConnecticutWe and others have recently shown that TEM do
not cause graft-versus-host disease (GVHD) in MHC-
matched and MHC-mismatched mouse strain pairings
[1-4]. Yet, after transfer, memory T cells can mount an
appropriate recall response in the recipient. However,
there is no a priori reason to suppose that the essential
features of memory phenotype cells will be different,
even if a larger component of mouse cells with this
phenotype arose by homeostatic proliferation [5,6].
We have been avidly investigating why
CD441CD62 ligand (CD62L)2TEM do not mediate
GVHD. At least 3 nonexclusive hypotheses could
explain this finding. First, TEM may not traffic suffi-
ciently to lymph nodes (LN) and Peyer’s patches (PP)
because of reduced expression of CD62L (also known
as L-selectin) and/or CC-chemokine receptor 7
(CCR7). Implicit in this idea is that these are required
sites for priming of TN. Second, TEM may have
a more restricted TCR repertoire that reduces the
frequency of alloreactive T cells below the threshold
necessary to induce GVHD. That TEM fail to induce
GVHD in MHC-mismatched models, in which the
overall frequency of alloreactive T cells among TN is
as high as 10%, makes this unlikely to be the only expla-
nation, although this hypothesis has not been fully
excluded. Also, as TEM can mediate graft-versus-leuke-
mia (GVL) (see below) and respond in mixed lympho-
cyte reactions against allogeneic stimulators indicates
that alloreactive cells are present among TEM. Third,
intrinsic properties of TEM— for example, reduced
clonal expansion—could prevent the development of
the complete GVHD syndrome [4].We have addressed the trafficking hypothesis in
some detail. To do so we used T cells deficient in
CD62L or CCR7, transplant recipients lacking
PNAd ligands for CD62L, and recipients without
LN, PP, or LN, PP, and spleen. Surprisingly, func-
tional CD62L and CCR7 were not required for TN-
mediated GVHD. Indeed, CCR72/2 T cells induced
GVHD in recipients lacking PNAd ligands. We
hypothesized that CD62L2/2 T cells might have
been primed in the spleen; however, CD62L2/2T cells
induced GVHD in splenectomized recipients. In mul-
tiple strain pairings GVHD developed in recipients
that lacked LN and PP. Mild GVHD could even be
induced in mice lacking all major secondary lymphoid
tissues (SLT). We unexpectedly observed in several
cases that altering the trafficking and priming site of
donor T cells affected the nature of GVHD. This phe-
nomenon manifested both when priming occurred in
the absence of the spleen or the PP/LN. In 3 MHC-
mismatched models, LN/PP-intact but splenectom-
ized recipients developed more rapidly lethal GVHD
than WT (spleen intact) recipients. In the 129/ B6
MHC-matched model, the lack of LN/PP promoted
the development of cutaneous GVHD. Conversely, en-
forced constitutive expression of CD62L on TEM did
not endow them with the ability to cause GVHD.
Taken together, these data argue against the hypothesis
that TEM fail to induce GVHD because of inefficient
trafficking to LN and PP. Moreover, these data indi-
cate that no specific site of priming is essential for
GVHD induction, although the GVHD phenotype
can be altered in the absence of individual SLTs.
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unprimed to recipient antigens, mediate GVL. We
performed these experiments in an the MHCII-
mismatched B6bm12B6 strain pairing to parallel the
dominant form of allorecognition in haploidentical
alloSCT. CD41 TEM mediated GVL against mouse
models of chronic phase and blast crisis chronic mye-
logenous leukemia (without causing GVHD), although
they were less potent inducers of GVL than were TN.
By creating gene-deficient leukemias and using per-
forin-deficient T cells we found that direct cytolytic
function is essential for TEM-mediated GVL, but that
GVL is retained when killing via FasL, TNF-a,
TRAIL, and perforin are individually impaired. How-
ever, TEM-mediated GVL was diminished when both
FasL and perforin pathways were blocked. In sum, these
results suggest that TEM retain sufficient cytolytic func-
tion to mediate GVL but lack other properties (eg., suf-
ficient clonal expansion) required to establish GVHD.REFERENCES
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the ability to maintain memory after exposure to anti-
gen [1-3]. However, results from several independent
studies published in the past several years suggest
that memory T cells do not cause graft-versus-host
disease (GVHD) [4-8]. These results have also led in-
vestigators to study further the ability of allospecific
memory T cells to induce GVHD [9-12]. In this re-
view, we describe the ability of nonalloreactive, cross-
reactive, and allospecific memory T cells to induce
GVHD and how these new concepts can be applied
in allogeneic hematopoietic cell transplantation.
NONALLOREACTIVE MEMORY T CELLS
The specificity of a memory T cell is determined
by the T cell receptor that is produced by random
gene rearrangement in thymus before it encounters
the specific antigen [13]. Because naı¨ve and memory
T cells are exclusive T cell subsets, memory T cell sub-
set should not contain host-antigen-specific T cells
and should not be able to induce GVHD if the donor
has not encountered antigens present in the host. Our
group has further demonstrated that, similar to effec-
tor memory T cells, central memory T cells are unable
to induce GVHD. GVHD-inducing T cells are exclu-
sively contained in naı¨ve phenotype T cells [8].Because most of the memory T cells if not all are non-
alloreactive in unprimed donors, the data described
above confirm that nonalloreactive T cells do not
induce GVHD.
CROSSREACTIVE MEMORY T CELLS
Even though it is very clear from the animal studies
that memory T cells from unprimed donors do not
contain allospecific T cells and do not cause GVHD
[4-8], concerns about the risk of GVHD remains espe-
cially when this approach is translated into humans
because the existence of nonallospecific but crossreac-
tive T cells [3]. These crossreactive T cells could be ac-
tivated by different environmental antigens and likely
crossreact with a wide variety of different epitopes or
different antigens. Thus, the alloresponses induced
by these cells will likely vary dramatically between
different donor-recipient pairs. Because of this, it
would be difficult to predict how different crossreac-
tive memory T cells react to alloantigens in GVH
reaction. However, there is evidence to suggest that
crossreactive memory T cells also have dramatically
decreased ability to induce GVHD [8]. Crossreactive
memory T cells do exist in unprimed donors because
equal IL-2 production was detected in purified mem-
ory T cells upon challenge with alloantigens despite
Memory T Cells 21the low proliferation and cytotoxicity as measured by
the optimal 5-day cultures, but these memory T cells
that are crossreactive to host antigens are unable to
cause GVHD. Although the reason why these cross-
reactive T cells cannot induce GVHD has not been
completely elucidated, it is known that the allores-
ponse mediated by these memory T cells cannot be
maintained in 5-day mixed lymphocyte cultures.
ALLOSPECIFIC MEMORY T CELLS
Another concern of selection of memory T cells is
the existence of true allospecific memory T cells in
some donors. Allospecific memory T cells can be gen-
erated after exposure to alloantigens in the form of
blood transfusion, prior transplantation, or pregnancy
[14]. Following organ transplantation, allospecific
memory T cells mediate faster and stronger immune
response than naı¨ve T cells [15]. In GVHD, results
from 2 different groups suggest that allospecific mem-
ory T cells have decreased ability to induce GVHD
compared with naı¨ve T cells [9,10]. To generate allo-
specific memory T cells, we first primed the donor
C57BL/6 mice with irradiated host BALB/c spleno-
cytes. More than 8 weeks later, we harvested T cells
from spleen and sorted them into naı¨ve and memory
T cells subsets based on their expression of CD62L.
The results demonstrate that CD62L2 from primed
donors, which mediate stronger in vitro proliferative
response, have decreased ability to mediate GVHD
compared with CD62L1 cells harvested from the
same animals. In contrast to unprimed donors,
CD62L2T cells from primed donor are able to induce
GVHD. Similar results have also been presented by
Dutt et al. [10]. It is important to point out that
these data are contrary to the data published by Zhang
et al. [11,12]. This group has demonstrated that
allospecific memory T cells harvested from GVHD
mice have increased ability to induce GVHD com-
pared with naı¨ve T cells. It is currently unclear why
allospecific memory T cells harvested from immu-
nized donors and from GVHD mice have different
ability to induce GVHD. Because all the current
models employ a heterozygous population of memory
T cells in which allospecific memory T cells represent
only a small subset of total T cells, a cleaner system
such as those using allospecific T cell repertoire (TCR)
transgenic T cells may be needed to answer this
question more definitely.




Results from pan T cell depletion (TCD) studies
indicate that the goal of any approach for prophylaxis
and treatment of GVHD is not only to preventGVHD, but also to preserve the beneficial effects me-
diated by T cells such as the antimalignancy as well as
antimicrobial effects [16]. Understanding the effects of
memory T cells on immune reconstitution, stem cell
engraftment, and antitumor effects would be impor-
tant prior to development of clinical trials.
Immune Reconstitution
T cell reconstitution posthematopoietic cell trans-
plantation primarily occurs through peripheral expan-
sion of mature T cells contained in the graft and/or
thymopoiesis [17]. We and others have demonstrated
that effector memory T cells can contribute directly
to posttransplantation T cell recovery [4,5]. We have
further demonstrated that memory T cells from un-
primed donors promote the generation of new T cells
from stem/progenitor cells [4]. These observations
have indicated that memory T cells contribute to post-
transplantation T cell reconstitution not only through
peripheral expansion but also through thymopoiesis.
These important observations suggest that memory
T cells are capable of protecting the stem cell recipi-
ents from infections early after transplantation by pro-
viding immediate recall immunity and later by
enhancing more diverse T cell regeneration through
thymopoiesis. Allospecific memory T cells are
expected to provide some early protection but would
likely impair thymopoiesis because they can induce
GVHD.
Engraftment
We also observed that host radioresistant T cells
were depleted in memory T cell recipients but not in
the T cell-depleted bone marrow control mice [4],
suggesting that memory T cells may be able to facili-
tate donor stem cell engraftment by reducing host im-
mune resistance. The observation that memory T cells
are able to respond initially but fail to maintain the
response (see above for detail) may explain why mem-
ory T cells are able to deplete host radioresistant cells
without causing GVHD. Most likely, this unique fea-
ture of memory T cells is caused by crossreactive mem-
ory T cells in response to alloantigens. Further studies
are required to understand this unique response.
Antitumor Effect
Initial results from proliferation assay suggest that,
similar to the response against alloantigens, unprimed
memory T cells’ response to tumor antigens is also
minimal [4]. Subsequent in vivo experiments have
demonstrated that unprimed memory T cells do have
direct antitumor potential [18,19]. Even though we
have not titrated the response by using quantitative
in vivo titration assays, the antitumor activity mediated
by unprimed memory T cells is unlikely as good as that
22 N. Chaomediated by naı¨ve T cells, because similar mechanisms
may account for the depletion of host radioresistant
cells and the inhibition of tumor growth and these
same T cells do not induce GVHD. Antitumor activity
by memory T cells could be enhanced by selecting
a donor who naturally carry tumor-associated anti-
gen-specific memory T cells or after vaccination of
the donor in vivo or ex vivo. Because memory T cells
enhance immune reconstitution through both periph-
eral expansion and thymopoiesis, antitumor activity
could also be enhanced through vaccination post
hematopoietic cell transplantation.
CLINICALTRANSLATION
Data from animal studies have indicated that both
nonalloreactive T cells and crossreactive T cells do not
induce GVHD [4-8], and allospecific T cells cause less
GVHD [9,10]. The major concern in using memory T
cells would be nonallospecific crossreactive T cells,
although in vitro testing suggest that human memory
T cells (CD45RA2) can proliferate but cannot elicit
cytotoxicity against alloantigens [20]. A clinical trial
will be needed to determine whether this approach
can be applied in humans to prevent GVHD. The
risk of GVHD might exist but should not be higher
compared with infusion of bulk T cells.
SUMMARY
Recent data have revealed marked differences in
alloresponses mediated by memory T cells during
GVH and host-versus-graft (HVG) reactions (summa-
rized in Table 1). Even though the mechanisms are not
completely understood, it is clear that all memory
T cells including nonallospecific, crossreactive, and
allospecific memory T cells have decreased ability to
induce GVHD. Selection of memory T cells or re-
moval of naı¨ve T cells will not only prevent GVHD,
but could also enhance immune reconstitution, facili-
tate engraftment, and have the potential to enhance
antitumor effects. A clinical trial has been planned.
Successful translation of this approach in the clinic
will improve the safety, enhance the effectiveness,
and broaden the scope of allogeneic hematopoietic
stem cell transplantation.
Table 1. Difference in Allogeneic Memory T Cell Responses during Host-
versus-Graft and Graft-versus-Host Response
Host-versus-Graft Graft-versus-Host
Naı¨ve 11 11
Nonalloreactive memory 2 2
Crossreactive memory 111 1/2
Allospecific memory 111 1
2indicates no response;1/2, with or without response;1, decreased
response;11, normal response;111, enhanced response.REFERENCES
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